Can arid1a expression levels in gastric carcinomas predict response to neoadjuvant therapy and prognosis?
Polish Journal of Pathology · 28.10.2026 · 77 (3) · 237-245
DOI: 10.5114/pjp/235688 ↗Kurz gefasst
Fachartikel in der Zeitschrift Polish Journal of Pathology, online erschienen am 28.10.2026. Verfasst von Sevinc Hallac Keser und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul, Turkey. Hauptthemen laut MEDLINE: Stomach Neoplasms, Neoadjuvant Therapy, Transcription Factors, DNA-Binding Proteins. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
The study aims to evaluate the significance of ARID1A expression in gastric cancer (GC) patients receiving neoadjuvant therapy, using immunohistochemical methods and bioinformatics approaches. Immunohistochemical analysis of an institutional clinical cohort (n = 80) was combined with bioinformatics analyses of independent public datasets. RNA-sequencing and clinical data from the TCGA-STAD cohort were retrieved and processed using TCGAbiolinks, differential expression analysis was performed using DESeq2, and overall survival (OS) was evaluated using Kaplan-Meier, log-rank, and univariate Cox regression analyses. STRING was used to construct an ARID1A-centered protein association network, while Human Protein Atlas and Cellosaurus data were used to evaluate ARID1A expression. Loss of ARID1A protein expression rate was 41.3%. ARID1A loss and larger tumor size were correlated (median 6.0 cm vs. 4.0 cm; p = 0.004). ARID1A status and histopathological response to neoadjuvant therapy, pathological tumor stage and OS are not statistically related. Bioinformatics analyses demonstrated marked variation in ARID1A expression across GC cell lines, while TCGA-STAD analyses showed no significant tumor-normal difference or survival association at the transcript level. While ARID1A loss is associated with increased tumor size, it is not a strong independent predictor of treatment response or OS in GC. These findings underscore the molecular complexity of gastric adenocarcinoma and the need for larger, multicenter studies to refine the clinical utility of ARID1A.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul, Turkey.
- Division of Medical Techniques and Services, Vocational School of Health Services, Demiroglu Science University, Istanbul, Turkey.
- Experimental Medicine Center, R&D Laboratory, Demiroglu Science University, Istanbul, Turkey.
- Istinye University Molecular Cancer Research Center (ISUMKAM), Istanbul, Turkey.
- Department of Medical Laboratory Techniques, Istinye University Vocational School of Health Care Services, Istanbul, Turkey.
- Department of Medical Oncology, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul, Turkey.
Zitieren
APA
Keser, S. H., Tunoglu, E. N. Y., Doğan, T., Sensu, S., Sengiz Erhan, S., Canoğlu, D., Çonay, E., Gül, A. E., & Barışık, N. Ö. (2026). Can arid1a expression levels in gastric carcinomas predict response to neoadjuvant therapy and prognosis?. Polish Journal of Pathology, 77(3), 237-245. https://doi.org/10.5114/pjp/235688
Vancouver
Keser SH, Tunoglu ENY, Doğan T, Sensu S, Sengiz Erhan S, Canoğlu D, et al. Can arid1a expression levels in gastric carcinomas predict response to neoadjuvant therapy and prognosis?. Polish Journal of Pathology. 2026;77(3):237-245. doi:10.5114/pjp/235688
BibTeX
@article{Keser2026,
author = {Keser, Sevinc Hallac and Tunoglu, Ezgi Nurdan Yenilmez and Doğan, Tunay and Sensu, Sibel and Sengiz Erhan, Selma and Canoğlu, Didem and Çonay, Erhan and Gül, Aylin Ege and Barışık, Nagehan Özdemir},
title = {Can arid1a expression levels in gastric carcinomas predict response to neoadjuvant therapy and prognosis?},
journal = {Polish Journal of Pathology},
year = {2026},
volume = {77},
number = {3},
pages = {237--245},
doi = {10.5114/pjp/235688}
}
EUVIMED